Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1545124 | 0.81 | KDM4E (0.49) | HTR2AHTR2CKCNH2KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL1838069 | 0.80 | KDM4E (0.51) | HTR2AHTR2CKCNH2KDM4EMAPT | |
| SCHEMBL7714021 | 0.75 | HTR2A (0.51) | HTR2AHTR2CKCNH2KDM4EDRD2 | |
| SCHEMBL31358121 | 0.75 | HTR2A (0.51) | HTR2AHTR2CKCNH2KDM4EDRD2 | |
| SCHEMBL2978037 | 0.75 | KDM4E (0.42) | HTR2AKDM4EMAPTDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3149408 | 0.73 | KDM4E (0.44) | KDM4EMAPTDRD2DRD3DRD4 | |
| SCHEMBL2201319 | 0.73 | KDM4E (0.41) | KDM4EMAPTDRD2DRD3DRD4 | |
| SCHEMBL2204018 | 0.73 | DRD2 (0.46) | HTR2AKDM4EMAPTDRD2DRD3 | |
| SCHEMBL8207212 | 0.73 | HTR2A (0.41) | HTR2AKCNH2KDM4EMAPTDRD2 | |
| SCHEMBL7965286 | 0.72 | DRD2 (0.41) | HTR2AKDM4EMAPTDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547452-B2 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080069885-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080063721-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7118763-B2 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES CONTROLLED THERAPEUTICS, INC. II (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060182810-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
| US-20050025828-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES CONTROLLED THERAPEUTICS INC. II (US) | 2005-02-03 | — | — | US | disclosed |
| EP-0729357-B1 | MICROENCAPSULATED 1,2-BENZAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-02 | — | — | EP | disclosed |
| US-6803055-B2 | SUSTAINED RELEASE; BENZAZOLE RING STRUCTURE; PSYCHOLOGICAL DISORDERS | ALKERMAS CONTROLLED THERAPEUTICS INC. II | 2004-10-12 | — | — | US | disclosed |
| US-20030165571-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES CONTROLLED THERAPEUTICS INC. II (US) | 2003-09-04 | — | — | US | disclosed |
| US-6544559-B2 | Such as 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9 -tetrahydro-2-methyl-4H-pyrido (1,2-a)pyrimidin-4-one for sustained-release via biodegradation; for treatment of mental illness | ALKERMES CONTROLLED THERAPEUTICS INC. II | 2003-04-08 | — | — | US | disclosed |
| CN-1024346-C | Preparation method of antihypertensive 3-piperidyl indazole derivative | JANSSEN PHARMACEUTICA NV (BE) | 1994-04-27 | — | — | CN | disclosed |
| CN-1022566-C | Process for preparing novel substituted 1-piperidinoalkylene-pyridopyrimidones or thiazolopyrimidinones | JANSSEN PHARMACEUTICA NV (BE) | 1993-10-27 | — | — | CN | disclosed |
| US-5196425-A | Antihypertensive 3-piperidinyl-indazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-23 | — | — | US | disclosed |
| EP-0196132-B1 | 1,2-BENZISOXAZOL-3-YL AND 1,2-BENZISOTHIAZOL-3-YL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-12 | — | — | EP | disclosed |
| CN-1040589-A | ANTIHYPERTENSIVE 3-PIPERIDINYL-INDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1990-03-21 | — | — | CN | disclosed |
| US-4804663-A | PSYCHOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-02-14 | — | — | US | disclosed |
| US-4804663-A | PSYCHOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-02-14 | — | — | US | disclosed |
| EP-0196132-A2 | 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-01 | — | — | EP | disclosed |
| EP-0196132-A2 | 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-01 | — | — | EP | disclosed |
| CN-86101906-A | Process for preparing 1, 2 benzisoxazol-3-yl and 1, 2 benzisothiazol-3-yl derivatives | — | 1986-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080069885-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | HTR2B, HTR7, HTR3D | HTR2A 12/4885HTR2C 6/4885KCNH2 3544/4885 |
| US-20050025828-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | CYP4X1, P2RX5, P2RX1 | HTR2A 319/4885HTR2C 146/4885KCNH2 3786/4885 |
| US-20060182810-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | CYP4X1, P2RX5, P2RX1 | HTR2A 319/4885HTR2C 146/4885KCNH2 3786/4885 |
| US-20030165571-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | CYP4X1, P2RX5, P2RX1 | HTR2A 319/4885HTR2C 146/4885KCNH2 3786/4885 |
| US-20080063721-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | HTR7, HTR2B, HTR1A | HTR2A 15/4885HTR2C 8/4885KCNH2 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.